{"entity":{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","aka":[],"tldr":"Built China's flagship biotherapy laboratory, a source of cancer vaccines, gene therapies, and biologics.","summary":"Yuquan Wei is Professor and Director of the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University. He founded the laboratory, China's flagship biotherapy institute and one of its largest translational cancer research centres, which has produced cancer vaccines, gene therapies and biologics, and he was president of Sichuan University. His publications include reviews of cancer vaccine platforms and progress, of mRNA vaccines as a therapeutic strategy, and of the CCL2-CCR2 signalling axis in cancer and its therapeutic targeting. His interests are cancer biotherapy, gene therapy, off-the-shelf and personalised neoantigen vaccines, and translational research.","asOf":"2026-09-08","links":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20YQ%5BAuthor%5D%20State%20Key%20Laboratory%20of%20Biotherapy"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["shared-antigen-vaccine","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["west-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-hematology-and-oncology","molecular-cancer"],"dependsOn":[],"notes":[],"role":"Professor; Director, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","institutionId":"west-china","specialisms":["Cancer biotherapy","Gene therapy","Vaccines","Translational research"],"profiles":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20YQ%5BAuthor%5D%20State%20Key%20Laboratory%20of%20Biotherapy"}],"papers":[{"title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","journal":"Journal of Hematology & Oncology","year":2022,"doi":"10.1186/s13045-022-01247-x"},{"title":"Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting","journal":"Cell Proliferation","year":2021,"doi":"10.1111/cpr.13115"},{"title":"mRNA vaccine: a potential therapeutic strategy","journal":"Molecular Cancer","year":2021,"doi":"10.1186/s12943-021-01311-z"}]},"route":"/people/wei-yuquan/","neighbours":{"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"institution":[{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/"}],"journal":[{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/"},{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/"}]}}